Poor response to thiopurine in inflammatory bowel disease: How to overcome therapeutic resistance?

Clinical Chemistry

Volumn 59, Issue 7, 2013, Pages 1023-1027

  Chouchana, Laurent ^a,b,c   Roche, Denis ^a   Jian, Raymond ^a,b   Beaune, Philippe ^a,b,c   Loriot, Marie Anne ^a,b,c  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

6 METHYLTHIOINOSINE; ADALIMUMAB; AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; STEROID; THIOPURINE METHYLTRANSFERASE; TIOGUANINE;

ADULT; ARTICLE; CASE REPORT; COLON ULCER; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MEDICAL HISTORY; PHARMACOLOGICAL PARAMETERS; RECURRENT DISEASE; STEROID THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; AZATHIOPRINE; COLITIS, ULCERATIVE; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RECURRENCE; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84879724086     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2012.195750     Document Type: Article

References (10)

1. Dervieux T, Boulieu R. Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. Clin Chem 1998;44:551-5. (Pubitemid 28141350)
2. Chouchana L, Narjoz C, Beaune P, Loriot M-A, Roblin X. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2012;35:15-36.
3. Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu MT, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002;122:904-15. (Pubitemid 34267273)
4. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui C-H, Yee SW, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 2011;89:387-91.
5. Hoentjen F, Hanauer SB, de Boer NK, Rubin DT. Two brothers with skewed thiopurine metabolism in ulcerative colitis treated successfully with allopurinol and mercaptopurine dose reduction. Dig Dis Sci 2012;57:250 -3.
6. van Egmond R, Chin P, Zhang M, Sies CW, Barclay ML. High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment. Aliment Pharmacol Ther 2012;35:1181-9.
7. Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 2007;5:209-14. (Pubitemid 46216945)
8. Oselin K, Anier K. Inhibition of human thiopurine S-methyltransferase by various nonsteroidal anti-inflammatory drugs in vitro: a mechanism for possible drug interactions. Drug Metab Dispos 2007;35:1452- 4.
9. Seinen ML, de Boer NKH, Smid K, van Asseldonk DP, Bouma G, van Bodegraven AA, et al. Allopurinol enhances the activity of hypoxanthineguanine phosphoribosyltransferase in inflammatory bowel disease patients during low-dose thiopurine therapy: preliminary data of an ongoing series. Nucleosides Nucleotides Nucleic Acids 2011;30:1085-90.
10. Blaker PA, Arenas M, Fairbanks L, Irving PM, Marinaki AM, Sanderson JI. A biochemical mechanism for the role of allopurinol in TPMT inhibition. Gastroenterology 2011;140:S769.